---
title: "Oncology estimand working group: task forces"
author: "A cross-industry international working group"
date: '02 Mar 2021'
output:
  html_document:
    keep_md: true
    toc: yes
    toc_depth: 2
    toc_float:
      collapsed: yes
      smooth_scroll: yes
      number_sections: true
  github_document: 
    toc: true
    toc_depth: 2
  pdf_document:
    toc: yes
  word_document:
    fig_caption: yes
    toc: yes
---



[Back to main site](http://www.oncoestimand.org)

# Members {.tabset .tabset-fade .tabset-pills} 


## Clinical engagement

**Lead**: Stefan Englert (AbbVie)

**Objective**: 


|Firstname |Lastname |Institution |Location |
|:---------|:--------|:-----------|:--------|
|Stefan    |Englert  |AbbVie      |EU       |
|Feng      |Liu      |AstraZeneca |NorAm    |
|Jonathan  |Siegel   |Bayer       |NorAm    |
|Emily     |Butler   |GSK         |NorAm    |
|Michelle  |Casey    |Pfizer      |NorAm    |
|Rui       |Tang     |Servier     |NorAm    |


## Propensity scores for treatment switching

**Lead**: character(0) character(0) (character(0))

**Objective**: 


|Firstname |Lastname |Institution |Location |
|:---------|:--------|:-----------|:--------|


## Patient-reported outcomes

**Lead**: Rachael Lawrence (Adelphi)

**Objective**: 


|Firstname |Lastname  |Institution |Location |
|:---------|:---------|:-----------|:--------|
|Rachael   |Lawrence  |Adelphi     |EU       |
|Xiangning |Huang     |AstraZeneca |EU       |
|Evgeny    |Degtyarev |Novartis    |EU       |
|Stephen   |Corson    |Phastar     |EU       |
|Jonathan  |Siegel    |Bayer       |NorAm    |


## Duration of responses

**Lead**: Hans-Jochen Weber (Novartis)

**Objective**: 


|Firstname     |Lastname     |Institution |Location |
|:-------------|:------------|:-----------|:--------|
|Alex          |Todd         |AstraZeneca |EU       |
|Martin-Oliver |Sailer       |Boehringer  |EU       |
|Hans-Jochen   |Weber        |Novartis    |EU       |
|Stephen       |Corson       |Phastar     |EU       |
|Jiang         |Li           |Beigene     |NorAm    |
|Steven        |Sun          |J&J         |NorAm    |
|Satrajit      |Roychoudhury |Pfizer      |NorAm    |
|Godwin        |Yung         |Roche       |NorAm    |


## Quantification of follow-up

**Lead**: Kaspar Rufibach (Roche)

**Objective**: 


|Firstname   |Lastname |Institution |Location |
|:-----------|:--------|:-----------|:--------|
|Lynda       |Grinsted |AstraZeneca |EU       |
|Hans-Jochen |Weber    |Novartis    |EU       |
|Kaspar      |Rufibach |Roche       |EU       |
|Jiang       |Li       |Beigene     |NorAm    |
|Jiangxiu    |Zhou     |GSK         |NorAm    |
|Yue         |Shentu   |Merck       |NorAm    |
|Cheng       |Zheng    |Sanofi      |NorAm    |


## Real-world data and estimands

**Lead**: Evgeny Degtyarev (Novartis)

**Objective**: 


|Firstname |Lastname  |Institution |Location |
|:---------|:---------|:-----------|:--------|
|Evgeny    |Degtyarev |Novartis    |EU       |
|Lisa      |Hampson   |Novartis    |EU       |
|Kaspar    |Rufibach  |Roche       |EU       |
|Feng      |Xiao      |AstraZeneca |NorAm    |
|Michelle  |Casey     |Pfizer      |NorAm    |
|Cheng     |Zheng     |Sanofi      |NorAm    |
|Rui       |Tang      |Servier     |NorAm    |
|Jianchang |Lin       |Takeda      |NorAm    |


## Conditional vs. marginal effects

**Lead**: Jiawei Wei (Novartis)

**Objective**: 


|Firstname |Lastname     |Institution |Location |
|:---------|:------------|:-----------|:--------|
|Bj√∂rn     |Bornkamp     |Novartis    |EU       |
|Kaspar    |Rufibach     |Roche       |EU       |
|Hong      |Tian         |J&J         |NorAm    |
|Satrajit  |Roychoudhury |Pfizer      |NorAm    |


## Time to event endpoints with prognostic or predictive biomarker subgroups

**Lead**: character(0) character(0) (character(0))

**Objective**: 


|Firstname |Lastname |Institution |Location |
|:---------|:--------|:-----------|:--------|
|Liwei     |Wang     |J&J         |NorAm    |

